Lilly strikes $1.6B deal to buy I-O player Armo Biosciences
Eli Lilly and Co. said it will buy Armo Biosciences Inc. for about $1.6 billion, in an all-cash transaction intended to bolster its immuno-oncology program through th...
From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment
Continue readingAdvertisement
Advertisement
Advertisement
Advertisement
Advertisement